A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

NCT05051579 on ClinicalTrials.gov · last registry update 2023-09-13

An unusually large phase 2: 272 participants, more than double the 110 typical for the stage. The sponsor logged completion for 25 August 2022. Primary outcome, as filed: Percent Change From Baseline in Body Weight in LY3502970 and Placebo. orforglipron is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: orforglipron
Foundayo
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 272
Started: 2021-09-29
Primary completion: 2022-08-25 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change From Baseline in Body Weight in LY3502970 and Placebo

Conditions studied

Obesity · Overweight and Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.